---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-25-000029"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T21:59:09.135883+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dexcom Q4 revenue $1.114B (+8% YoY); GAAP EPS $0.38; FY2025 guidance $4.6B

## Summary
- Q4 revenue $1.114B (+8% YoY); U.S. +4%, international +17% reported.
- GAAP net income $151.7M ($0.38 diluted EPS) vs $256.3M ($0.62) YoY; non-GAAP EPS $0.45 vs $0.50.
- Full year 2024 revenue $4.033B (+11% YoY); GAAP operating margin 14.9% (-160bps); non-GAAP margin 18.8% (-100bps).
- Submitted G7 15-day CGM to FDA; secured Dexcom ONE+ reimbursement in France; partnership with ŌURA.
- FY2025 guidance: revenue $4.60B (+14% growth); non-GAAP gross margin ~64-65%; operating margin ~21%; Adj. EBITDA ~30%.

## SEC filing metadata
- accession: 0001093557-25-000029
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000029/0001093557-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000029/dxcm-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-25-000029
- JSON: https://secwatch.observer/filing/0001093557-25-000029.json
- Plain text: https://secwatch.observer/filing/0001093557-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.